Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06103916

Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice

Multicenter prospective cohort study in which patients ≥18 years with an ovarian tumor for which an ultrasound has been performed in accordance with IOTA criteria and the IOTA ADNEX model has been applied are included. Ultrasound data from these patients will be prospectively recorded in a database to determine the diagnostic accuracy of the IOTA ADNEX model in Dutch gynaecological practice.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Máxima Medical Centre

Veldhoven, North Brabant, 5504 DB, Netherlands

Location status: Recruiting

Location contact

Esther Lems, MD

CONTACT

[email protected]

+31408888380

About this study

Rationale: Correct pre-operative classification of ovarian tumors is critical for optimal treatment of both women with benign and malignant ovarian tumors. The International Ovarian Tumor Analysis (IOTA) consortium developed several risk-assessment strategies, including the Assessment of Different NEoplasias in the adneXa (ADNEX) model. This is a polytomous model that estimates the risk of malignancy in women with an ovarian tumor and can help differentiate benign from malignant ovarian tumors. Recent validation studies have shown superior diagnostic accuracy of the ADNEX model compared with previously developed risk-assessment strategies. However, the diagnostic accuracy of this model in daily clinical practice is still unknown. Furthermore, expertise is necessary to use this model before the results are reliable. With the recently published Dutch guideline on risk-assessment strategies of ovarian tumors, in which it is advised to use the ADNEX model, clinical data on diagnostic performance of the ADNEX model in daily Dutch gynaecological practice are necessary. Lower sensitivity and/or specificity of the model will have significant influence on the referral practice in The Netherlands.

Objective: To determine the diagnostic accuracy of the IOTA ADNEX model in the discrimination between benign and malignant ovarian tumors in daily gynaecological practice in The Netherlands.

Study design: Multicentre prospective cohort study. Hospitals from three oncologic networks in the Netherlands will participate in this trial. Ultrasound data will be prospectively recorded in a database for a duration of five years by means of an electronic case report form (eCRF). With these data, the diagnostic accuracy of the IOTA ADNEX model will be calculated.

Study population: All women ≥ 18 years with an ovarian tumor for which ultrasound assessment in accordance with the IOTA definitions has been performed and the ADNEX model has been applied. Women with a tumor that meets the IOTA criteria of a benign 'easy descriptor' will be excluded.

Data collection: All patients eligible for this study will be asked for informed consent and clinical data will be collected through eCRFs. Data will be collected in a cloud-based database by the treating physician.

Main study parameters/endpoints: The sensitivity, specificity and area under the curve of the IOTA ADNEX model.

Secondary analysis: Secondary endpoints include the influence of practice variation (eg type of center, volume per center, prevalence of malignancy, availability of consultation time specifically aimed at performing ultrasounds according to IOTA criteria) and the experience of the ultrasound performer on the diagnostic accuracy of the IOTA ADNEX model.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Presence of a complex ovarian tumor
  • Ultrasound assessment in accordance with IOTA definitions and application of the ADNEX model
  • Understanding of Dutch language

Exclusion criteria

  • Women with an ovarian tumor that meets the IOTA criteria of a benign easy descriptor:
  • Unilocular tumor with ground glass echogenicity in premenopausal woman suggestive of endometrioma
  • Unilocular tumor with mixed echogenicity and acoustic shadows in premenopausal women (suggestive of benign cystic teratoma)
  • Unilocular tumor with regular walls and maximal diameter < 10cm (suggestive of simple cyst or cystadenoma)
  • Remaining unilocular tumors with regular walls
  • Histologically proven malignancy prior to ultrasound

Treatment and study plan

Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.

Other

From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.

Primary outcomes

  1. Diagnostic accuracy of the IOTA ADNEX model

    Time frame: 5 years (2022 - 2027)

    Area under the curve (AUC)

  2. Sensitivity and specificity

    Time frame: 5 years (2022 - 2027)

    Sensitivity and specificity of the IOTA ADNEX model (%) at different thresholds

Secondary outcomes

  1. Factors influencing the diagnostic performance of the IOTA ADNEX model

    Time frame: 5 years (2022 - 2027)

    Influence on the diagnostic performance of the type of center, volume per center, prevalence of malignancy, experience of ultrasound performer, availability of consultation time specifically aimed at performing ultrasounds according to IOTA criteria

Study contacts

Contact information is provided by the study sponsor or research team.

Esther Lems, MD

CONTACT

[email protected]

+31 40 888 83 80

Peggy Geomini, PhD

CONTACT

[email protected]

+31 40 888 83 80

Sponsors and collaborators

Lead sponsor

Maxima Medical Center

Other

Collaborators

  • Catharina Ziekenhuis Eindhoven
  • Radboud University Medical Center
  • The Netherlands Cancer Institute
  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Acronym: PRIORITY

Important dates

Study start
2022
Primary completion
2027
Study completion
2028
First posted
Oct 27, 2023
Registry last updated
Oct 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.